Oppenheimer Maintains Outperform on Enovix, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 95.9%

Neg 95.9% Neu 0% Pos 0%

Oppenheimer analyst Colin Rusch maintains Enovix (NASDAQ:ENVX) with a Outperform and lowers the price target from $24 to $21.